Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Lack of overall survival benefit for aromatase inhibitors examined

By News Team

Cumulative toxicity may explain the low overall survival benefit of aromatase inhibitors (AIs) despite improvements in breast cancer-free survival, according to a recent meta-analysis (Journal of the National Cancer Institute 2011;103:1).

Researchers analysed data from seven randomised trials including 30,023 postmenopausal women with early-stage breast cancer. They found that, compared with tamoxifen, the use of AIs as first-line adjuvant treatment was associated with an increased risk of cardiovascular disease and bone fractures, and a reduced risk of venous thrombosis and endometrial cancer.


Citation: Clinical Pharmacist URI: 11083349

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.